NCT02483260View on ClinicalTrials.gov

Intravenous Ribavirin Protocol to Treat Individuals With Viral Hemorrhagic Fever

NAEnrolling by invitationINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 16, 2016

Primary Completion Date

October 31, 2027

Study Completion Date

December 31, 2028

Conditions
Viral Hemorrhagic Fever
Interventions
DRUG

Ribavirin

"1. Loading dose, 33 mg/kg (maximum dose: 2.64 g)~2. Followed in 6 hours by a dose of 16 mg/kg (maximum dose: 1.28 g) every 6 hours for the first 4 days (15 doses)~3. Followed by a dose of 8 mg/kg (maximum dose: 0.64 g) every 8 hours for the subsequent 6 days (18 doses)."

Trial Locations (1)

09180

Landstuhl Regional Medical Center, Landstuhl

All Listed Sponsors
lead

U.S. Army Medical Research and Development Command

FED